



(51) International Patent Classification:  
*A61K 31/19* (2006.01)

(21) International Application Number:  
PCT/US2013/031051

(22) International Filing Date:  
13 March 2013 (13.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/620,953 5 April 2012 (05.04.2012) US

(71) Applicant: **CHDI FOUNDATION, INC.** [US/US]; 350  
Seventh Avenue, Suite 601, New York, NY 10001 (US).

(72) Inventors: **TOLEDO-SHERMAN, Leticia, M;** 3015  
Goldsmith Street, Santa Monica, CA 90405 (US).  
**DOMINGUEZ, Celia;** 8606 Allenwood Road, Los  
Angeles, CA 90046 (US). **PRIME, Michael;** 7 Overmead,  
Abingdon Oxfordshire OX14 5NB (GB). **MITCHELL,**  
**William, Leonard;** Hunters Meet, Chapel Lane, Swallow,  
Market Rasen Lincolnshire LN7 6DE (GB). **JOHNSON,**  
**Peter;** 59 Overmead, Abingdon Oxfordshire OX14 5ND  
(GB). **WENT, Naomi;** 13 Weavercroft, Didcot Oxford-  
shire OX11 7RR (GB).

(74) Agents: **STEVENS, Lauren, L.** et al.; Global Patent  
Group, LLC, 1005 N. Warson Rd., Suite 404, St Louis,  
MO 63132 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,  
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,  
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))

**Published:**

— with international search report (Art. 21(3))

(54) Title: KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS  
OF USE THEREOF

(57) Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions compris-  
ing the same and methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO  
activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically ac-  
ceptable salt or prodrug thereof described herein, effective to reduce signs or symptoms of the disease or disorder. These diseases in-  
clude neurodegenerative disorders such as Huntington's disease.

